{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:11:19Z","timestamp":1781820679970,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Comorbid autoimmune disorders, including rheumatoid arthritis (RA), are common in people with multiple sclerosis (MS). Both conditions share pathogenic similarities, enabling potential overlap in treatments. While numerous disease-modifying therapies (DMT) are approved for MS and new options are under clinical trial, their effectiveness in RA varies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main body<\/jats:title>\n            <jats:p>A PubMed literature review was conducted to evaluate the effects of approved and currently investigated MS-DMT on MS and RA and vice versa. Certain MS-DMT showed beneficial effects for RA, such as teriflunomide, anti-CD20 therapies, and cladribine, while others demonstrated no significant impact (type-I interferons, Bruton\u00b4s tyrosine kinase (BTK) inhibitors) or lacked trials (sphingosine-1-phosphate receptor modulators, glatiramer acetate). In contrast, BTK inhibitors were shown to be effective for inactive secondary progressive forms of MS, whereas secukinumab showed limited effects in relapsing MS. Concerning DMT for RA in MS, no significant benefit was observed for abatacept, and there are no trials for Janus kinase inhibitors, or interleukin-(IL)-6 receptor inhibitors (tocilizumab, sarilumab). Adverse events, including RA exacerbation, were reported for some MS-DMT like dimethyl fumarate, alemtuzumab, and natalizumab. Tumor necrosis factor alpha (TNF\u03b1) inhibitors increased disease activity in MS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among approved DMT for MS and RA, teriflunomide and anti-CD20 therapies are the most suitable options for moderately or highly active MS with comorbid RA. Cladribine may also be considered, while TNF\u03b1 inhibitors are contraindicated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00414-y","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:41:49Z","timestamp":1752777709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis"],"prefix":"10.1186","volume":"7","author":[{"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"1","key":"414_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42466-024-00310-x","volume":"6","author":"A Bayas","year":"2024","unstructured":"Bayas, A., Mansmann, U., \u00d6n, B. I., Hoffmann, V. S., Berthele, A., M\u00fchlau, M., Kowarik, M. C., Krumbholz, M., Senel, M., Steuerwald, V., Naumann, M., Hartberger, J., Kerschensteiner, M., Oswald, E., Ruschil, C., Ziemann, U., Tumani, H., Vardakas, I., Albashiti, F., Kramer, F., ProVal, & -MS study group. (2024). Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study. Neurological Research and Practice, 6(1), 15. https:\/\/doi.org\/10.1186\/s42466-024-00310-x","journal-title":"Neurological Research and Practice"},{"issue":"1","key":"414_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s42466-024-00351-2","volume":"6","author":"KF Jendretzky","year":"2024","unstructured":"Jendretzky, K. F., Lezius, L. M., Thiele, T., Konen, F. F., Huss, A., Heitmann, L., G\u00fczeloglu, Y. E., Schwenkenbecher, P., S\u00fchs, K. W., Skuljec, J., Wattjes, M. P., Witte, T., Kleinschnitz, C., Pul, R., Tumani, H., Gingele, S., & Skripuletz, T. (2024). Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients. Neurological Research and Practice, 6(1), 55. https:\/\/doi.org\/10.1186\/s42466-024-00351-2","journal-title":"Neurological Research and Practice"},{"issue":"5","key":"414_CR3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00415-012-6790-1","volume":"260","author":"R Dobson","year":"2013","unstructured":"Dobson, R., & Giovannoni, G. (2013). Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. Journal of Neurology, 260(5), 1272\u20131285. https:\/\/doi.org\/10.1007\/s00415-012-6790-1","journal-title":"Journal of Neurology"},{"issue":"23","key":"414_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine, 365(23), 2205\u20132219. https:\/\/doi.org\/10.1056\/NEJMra1004965","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"414_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1), 43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nature Reviews Disease Primers"},{"issue":"5","key":"414_CR6","doi-asserted-by":"publisher","first-page":"103312","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"FF Konen","year":"2023","unstructured":"Konen, F. F., M\u00f6hn, N., Witte, T., Schefzyk, M., Wiestler, M., Lovric, S., Hufendiek, K., Schwenkenbecher, P., S\u00fchs, K. W., Friese, M. A., Klotz, L., Pul, R., Pawlitzki, M., Hagin, D., Kleinschnitz, C., Meuth, S. G., & Skripuletz, T. (2023). Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmunity Reviews, 22(5), 103312. https:\/\/doi.org\/10.1016\/j.autrev.2023.103312","journal-title":"Autoimmunity Reviews"},{"issue":"12","key":"414_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","volume":"81","author":"W Xie","year":"2024","unstructured":"Xie, W., Sun, Y., Zhang, W., Zhu, N., & Xiao, S. (2024). Risk of inflammatory central nervous system diseases after tumor necrosis factor-inhibitor treatment for autoimmune diseases: a systematic review and meta-analysis. JAMA Neurol, 81(12), 1284\u20131294. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3524","journal-title":"JAMA Neurol"},{"issue":"8","key":"414_CR8","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1021\/jm301848w","volume":"56","author":"H Munier-Lehmann","year":"2013","unstructured":"Munier-Lehmann, H., Vidalain, P. O., Tangy, F., & Janin, Y. L. (2013). On dihydroorotate dehydrogenases and their inhibitors and uses. Journal of Medicinal Chemistry, 56(8), 3148\u20133167. https:\/\/doi.org\/10.1021\/jm301848w","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"414_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","volume":"43","author":"JT Sharp","year":"2000","unstructured":"Sharp, J. T., Strand, V., Leung, H., Hurley, F., & Loew-Friedrich, I. (2000). Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide rheumatoid arthritis investigators group. Arthritis and Rheumatism, 43(3), 495\u2013505.","journal-title":"Arthritis and Rheumatism"},{"issue":"490","key":"414_CR10","doi-asserted-by":"publisher","first-page":"eaao5563","DOI":"10.1126\/scitranslmed.aao5563","volume":"11","author":"L Klotz","year":"2019","unstructured":"Klotz, L., Eschborn, M., Lindner, M., Liebmann, M., Herold, M., Janoschka, C., Torres Garrido, B., Schulte-Mecklenbeck, A., Gross, C. C., Breuer, J., Hundehege, P., Posevitz, V., Pignolet, B., Nebel, G., Glander, S., Freise, N., Austermann, J., Wirth, T., Campbell, G. R., Schneider-Hohendorf, T., & Wiendl, H. (2019). Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Science Translational Medicine, 11(490), eaao5563. https:\/\/doi.org\/10.1126\/scitranslmed.aao5563","journal-title":"Science Translational Medicine"},{"issue":"4","key":"414_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40268-019-00286-z","volume":"19","author":"A Muehler","year":"2019","unstructured":"Muehler, A., Kohlhof, H., Groeppel, M., & Vitt, D. (2019). The selective oral immunomodulator vidofludimus in patients with active rheumatoid arthritis: safety results from the COMPONENT study. Drugs in R&D, 19(4), 351\u2013366. https:\/\/doi.org\/10.1007\/s40268-019-00286-z","journal-title":"Drugs in R&amp;D"},{"key":"414_CR12","doi-asserted-by":"publisher","unstructured":"Fox, R. J., Wiendl, H., Wolf, C., De Stefano, N., Sellner, J., Gryb, V., Rejdak, K., Bozhinov, P. S., Vitt, D., Kohlhof, H., Slizgi, J., Ondrus, M., Sciacca, V., & Muehler, A. R. & EMPhASIS investigators. (2024). Safety and dose-response of vidofludimus calcium in relapsing multiple sclerosis: extended results of a placebo-controlled Phase 2 Trial. Neurology(R) neuroimmunology & neuroinflammation, 11(3), e200208. https:\/\/doi.org\/10.1212\/NXI.0000000000200208","DOI":"10.1212\/NXI.0000000000200208"},{"issue":"1","key":"414_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak, T., & Robak, E. (2011). New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs: Clinical Immunotherapeutics Biopharmaceuticals and Gene Therapy, 25(1), 13\u201325. https:\/\/doi.org\/10.2165\/11539590-000000000-00000","journal-title":"BioDrugs: Clinical Immunotherapeutics Biopharmaceuticals and Gene Therapy"},{"issue":"17","key":"414_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMc1702076","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X., Belachew, S., & Wolinsky, J. S. (2017). Ocrelizumab in primary progressive and relapsing multiple sclerosis. The New England Journal of Medicine, 376(17), 1694. https:\/\/doi.org\/10.1056\/NEJMc1702076","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"414_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., Selmaj, K., Wiendl, H., Kerloeguen, C., Willi, R., Li, B., Kakarieka, A., Tomic, D., Goodyear, A., Pingili, R., H\u00e4ring, D. A., & ASCLEPIOS II Trial Groups. (2020). Ofatumumab versus teriflunomide in multiple sclerosis. The New England Journal of Medicine, 383(6), 546\u2013557. ASCLEPIOS I. https:\/\/doi.org\/10.1056\/NEJMoa1917246","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"414_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman, L., Fox, E., Hartung, H. P., Alvarez, E., Qian, P., Wray, S., Robertson, D., Huang, D., Selmaj, K., Wynn, D., Cutter, G., Mok, K., Hsu, Y., Xu, Y., Weiss, M. S., Bosco, J. A., Power, S. A., Lee, L., Miskin, H. P., Cree, B. A. C., ULTIMATE I and ULTIMATE II Investigators., et al. (2022). Ublituximab versus teriflunomide in relapsing multiple sclerosis. The New England Journal of Medicine, 387(8), 704\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa2201904","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"414_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson, A., Frisell, T., Burman, J., Salzer, J., Fink, K., Hallberg, S., Hambraeus, J., Axelsson, M., Nimer, F. A., Sundstr\u00f6m, P., Gunnarsson, M., Johansson, R., Mellerg\u00e5rd, J., Rosenstein, I., Ayad, A., Sj\u00f6blom, I., Risedal, A., de Flon, P., Gilland, E., Lindeberg, J., Shawket, F., Piehl, F., & Lycke, J. (2022). Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in sweden: A rater-blinded, phase 3, randomised controlled trial. Lancet Neurololgy, 21(8), 693\u2013703. https:\/\/doi.org\/10.1016\/S1474-4422(22)00209-5","journal-title":"Lancet Neurololgy"},{"issue":"2","key":"414_CR18","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","volume":"9","author":"P Emery","year":"2014","unstructured":"Emery, P., Rigby, W., Tak, P. P., D\u00f6rner, T., Olech, E., Martin, C., Millar, L., Travers, H., & Fisheleva, E. (2014). Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PloS One, 9(2), e87379. https:\/\/doi.org\/10.1371\/journal.pone.0087379","journal-title":"PloS One"},{"issue":"6","key":"414_CR19","doi-asserted-by":"publisher","first-page":"e0157961","DOI":"10.1371\/journal.pone.0157961","volume":"11","author":"E Quattrocchi","year":"2016","unstructured":"Quattrocchi, E., \u00d8stergaard, M., Taylor, P. C., van Vollenhoven, R. F., Chu, M., Mallett, S., Perry, H., & Kurrasch, R. (2016). Safety of repeated open-label treatment courses of intravenous ofatumumab, a human Anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials. PloS One, 11(6), e0157961. https:\/\/doi.org\/10.1371\/journal.pone.0157961","journal-title":"PloS One"},{"issue":"1","key":"414_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2165\/00003088-200039010-00002","volume":"39","author":"SA Johnson","year":"2000","unstructured":"Johnson, S. A. (2000). Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clinical Pharmacokinetics, 39(1), 5\u201326. https:\/\/doi.org\/10.2165\/00003088-200039010-00002","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"414_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Soelberg S\u00f8rensen, P., Vermersch, P., Chang, P., Hamlett, A., Musch, B., Greenberg, S. J., & CLARITY Study Group. (2010). A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England Journal of Medicine, 362(5), 416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"414_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3109\/03009749709065702","volume":"26","author":"M Schirmer","year":"1997","unstructured":"Schirmer, M., Mur, E., Pfeiffer, K. P., Thaler, J., & Konwalinka, G. (1997). The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scandinavian Journal of Rheumatology, 26(5), 376\u2013379. https:\/\/doi.org\/10.3109\/03009749709065702","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"9139","key":"414_CR23","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"Randomised double-blind","year":"1998","unstructured":"Randomised double-blind. (1998). placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple Sclerosis) study group. Lancet (London England), 352(9139), 1498\u20131504.","journal-title":"Lancet (London England)"},{"issue":"4","key":"414_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/rheumatology\/38.4.362","volume":"38","author":"PP Tak","year":"1999","unstructured":"Tak, P. P., Hart, B. A., Kraan, M. C., Jonker, M., Smeets, T. J., & Breedveld, F. C. (1999). The effects of interferon beta treatment on arthritis. Rheumatology (Oxford England), 38(4), 362\u2013369. https:\/\/doi.org\/10.1093\/rheumatology\/38.4.362","journal-title":"Rheumatology (Oxford England)"},{"issue":"1","key":"414_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/ard.2003.020347","volume":"64","author":"J van Holten","year":"2005","unstructured":"van Holten, J., Pavelka, K., Vencovsky, J., Stahl, H., Rozman, B., Genovese, M., Kivitz, A. J., Alvaro, J., Nuki, G., Furst, D. E., Herrero-Beaumont, G., McInnes, I. B., Musikic, P., & Tak, P. P. (2005). A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 64(1), 64\u201369. https:\/\/doi.org\/10.1136\/ard.2003.020347","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"414_CR26","doi-asserted-by":"publisher","first-page":"CD010227","DOI":"10.1002\/14651858.CD010227.pub2","volume":"2016","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood, G. S., Barnabe, C., Tomlinson, G., Marshall, D., Devoe, D. J., & Bombardier, C. (2016). Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. The Cochrane Database of Systematic Reviews, 2016(8), CD010227. https:\/\/doi.org\/10.1002\/14651858.CD010227.pub2","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"6","key":"414_CR27","doi-asserted-by":"publisher","first-page":"CD008933","DOI":"10.1002\/14651858.CD008933.pub2","volume":"2013","author":"G Filippini","year":"2013","unstructured":"Filippini, G., Del Giovane, C., Vacchi, L., D\u2019Amico, R., Di Pietrantonj, C., Beecher, D., & Salanti, G. (2013). Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. The Cochrane Database of Systematic Reviews, 2013(6), CD008933. https:\/\/doi.org\/10.1002\/14651858.CD008933.pub2","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"12","key":"414_CR28","doi-asserted-by":"publisher","first-page":"CD015005","DOI":"10.1002\/14651858.CD015005.pub2","volume":"12","author":"B Ridley","year":"2024","unstructured":"Ridley, B., Nonino, F., Baldin, E., Casetta, I., Iuliano, G., & Filippini, G. (2024). Azathioprine for people with multiple sclerosis. The Cochrane Database of Systematic Reviews, 12(12), CD015005. https:\/\/doi.org\/10.1002\/14651858.CD015005.pub2","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"10","key":"414_CR29","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-019-04595-1","volume":"38","author":"Y Huang","year":"2019","unstructured":"Huang, Y., Fan, Y., Liu, Y., Xie, W., & Zhang, Z. (2019). Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. Clinical Rheumatology, 38(10), 2765\u20132776. https:\/\/doi.org\/10.1007\/s10067-019-04595-1","journal-title":"Clinical Rheumatology"},{"key":"414_CR30","doi-asserted-by":"publisher","first-page":"107925","DOI":"10.1016\/j.pharmthera.2021.107925","volume":"229","author":"F Kolbinger","year":"2022","unstructured":"Kolbinger, F., Di Padova, F., Deodhar, A., Hawkes, J. E., Huppertz, C., Kuiper, T., McInnes, I. B., Ritchlin, C. T., Rosmarin, D., Schett, G., Carballido, J. M., H\u00e4usermann, P., Calonder, C., Vogel, B., Rondeau, J. M., & Bruin, G. (2022). Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics, 229, 107925. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107925","journal-title":"Pharmacology &amp; Therapeutics"},{"issue":"7","key":"414_CR31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdov\u00e1","year":"2016","unstructured":"Havrdov\u00e1, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., Garren, H., Maguire, R. P., & Johns, D. R. (2016). Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. Journal of Neurology, 263(7), 1287\u20131295. https:\/\/doi.org\/10.1007\/s00415-016-8128-x","journal-title":"Journal of Neurology"},{"issue":"6","key":"414_CR32","doi-asserted-by":"publisher","first-page":"e13943","DOI":"10.1111\/dth.13943","volume":"33","author":"F Di Tullio","year":"2020","unstructured":"Di Tullio, F., Odorici, G., Lasagni, C., Capobianco, M., Conti, A., & Mandel, V. D. (2020). Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatologic Therapy, 33(6), e13943. https:\/\/doi.org\/10.1111\/dth.13943","journal-title":"Dermatologic Therapy"},{"key":"414_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","volume":"31","author":"M Diebold","year":"2019","unstructured":"Diebold, M., M\u00fcller, S., Derfuss, T., & D\u00e9card, B. F. (2019). A case of concomitant psoriasis and multiple sclerosis: secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. Multiple Sclerosis and Related Disorders, 31, 38\u201340. https:\/\/doi.org\/10.1016\/j.msard.2019.03.009","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"11","key":"414_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese, M. C., Becker, J. C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, R., Hagerty, D. T., & Dougados, M. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine, 353(11), 1114\u20131123. https:\/\/doi.org\/10.1056\/NEJMoa050524","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"414_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1177\/1352458516662727","volume":"23","author":"SJ Khoury","year":"2017","unstructured":"Khoury, S. J., Rochon, J., Ding, L., Byron, M., Ryker, K., Tosta, P., Gao, W., Freedman, M. S., Arnold, D. L., Sayre, P. H., Smilek, D. E., & ACCLAIM Study Group. (2017). ACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills Basingstoke England), 23(5), 686\u2013695. https:\/\/doi.org\/10.1177\/1352458516662727","journal-title":"Multiple Sclerosis (Houndmills Basingstoke England)"},{"issue":"12","key":"414_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","volume":"21","author":"MD Stanchina","year":"2024","unstructured":"Stanchina, M. D., Montoya, S., Danilov, A. V., Castillo, J. J., Alencar, A. J., Chavez, J. C., Cheah, C. Y., Chiattone, C., Wang, Y., Thompson, M., Ghia, P., Taylor, J., & Alderuccio, J. P. (2024). Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nature Reviews Clinical Oncology, 21(12), 867\u2013887. https:\/\/doi.org\/10.1038\/s41571-024-00956-1","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"10","key":"414_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/13543784.2020.1807934","volume":"29","author":"S Torke","year":"2020","unstructured":"Torke, S., & Weber, M. S. (2020). Inhibition of bruton\u00b4s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opinion on Investigational Drugs, 29(10), 1143\u20131150. https:\/\/doi.org\/10.1080\/13543784.2020.1807934","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"414_CR38","doi-asserted-by":"crossref","unstructured":"Montalban, X., Vermersch, P., Arnold, D. L., Bar-Or, A., Cree, B. A. C., Cross, A.H., Kubala Havrdova, E., Kappos, L., Stuve, O., Wiendl, H., Wolinsky, J. S., Dahlke,F., Le Bolay, C., Shen Loo, L., Gopalakrishnan, S., Hyvert, Y., Javor, A., Guehring,H., Tenenbaum, N., Tomic, D.,\u2026 evolutionRMS investigators (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2):two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet. Neurology, 23(11), 1119\u20131132. doi: 10.1016\/S1474-4422(24)00328-4","DOI":"10.1016\/S1474-4422(24)00328-4"},{"key":"414_CR39","doi-asserted-by":"crossref","unstructured":"Oh, J., Arnold, D. L., Cree, B. A. C., Ionete, C., Kim, H. J., Sormani, M. P. (2024).; on behalf of the tolebrutinib phase 3 GEMINI 1 and 2 trial group efficacy and safety of tolebrutinib versus teriflunomide in relapsing multiple sclerosis: results from the phase 3 GEMINI 1 and 2 trials. ECTRIMS 2024, Copenhagen.","DOI":"10.1016\/j.msard.2024.106115"},{"key":"414_CR40","doi-asserted-by":"crossref","unstructured":"Fox, R. J., Bar-Or, A., Traboulsee, A., Orjea-Guevara, C., Giovannoni, G., Vermersch, P., & on behalf of the Tolebrutinib Phase 3 HERCULES Trial Group. (2024). Efficacy and safety of tolebrutinib versus placebo in non-relapsing secondary progressive multiple sclerosis: results from the phase 3 HERCULES Trial. ECTRIMS 2024, Copenhagen.","DOI":"10.1016\/j.msard.2024.106114"},{"issue":"1","key":"414_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","volume":"7","author":"PH Schafer","year":"2020","unstructured":"Schafer, P. H., Kivitz, A. J., Ma, J., Korish, S., Sutherland, D., Li, L., Azaryan, A., Kosek, J., Adams, M., Capone, L., Hur, E. M., Hough, D. R., & Ringheim, G. E. (2020). Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study. Rheumatology and Therapy, 7(1), 101\u2013119. https:\/\/doi.org\/10.1007\/s40744-019-00182-7","journal-title":"Rheumatology and Therapy"},{"issue":"9","key":"414_CR42","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.41275","volume":"72","author":"S Cohen","year":"2020","unstructured":"Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Galanter, J., Lee, C., Rae, J., Toth, B., Ramamoorthi, N., Hackney, J. A., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Chinn, L. W., Townsend, M. J., Morimoto, A. M., & Genovese, M. C. (2020). Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES Study). Arthritis & Rheumatology (Hoboken N J), 72(9), 1435\u20131446. https:\/\/doi.org\/10.1002\/art.41275","journal-title":"Arthritis &amp; Rheumatology (Hoboken N J)"},{"issue":"7","key":"414_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3899\/jrheum.200893","volume":"48","author":"MC Genovese","year":"2021","unstructured":"Genovese, M. C., Spindler, A., Sagawa, A., Park, W., Dudek, A., Kivitz, A., Chao, J., Chan, L., Witcher, J., Barchuk, W., & Nirula, A. (2021). Safety and efficacy of poseltinib, bruton\u2019s tyrosine kinase inhibitor, in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase II study. The Journal of Rheumatology, 48(7), 969\u2013976. https:\/\/doi.org\/10.3899\/jrheum.200893","journal-title":"The Journal of Rheumatology"},{"issue":"4","key":"414_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","volume":"35","author":"R Roy","year":"2021","unstructured":"Roy, R., Alotaibi, A. A., & Freedman, M. S. (2021). Sphingosine 1-phosphate receptor modulators for multiple sclerosis. CNS Drugs, 35(4), 385\u2013402. https:\/\/doi.org\/10.1007\/s40263-021-00798-w","journal-title":"CNS Drugs"},{"issue":"10306","key":"414_CR45","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","volume":"398","author":"MP McGinley","year":"2021","unstructured":"McGinley, M. P., & Cohen, J. A. (2021). Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet (London England), 398(10306), 1184\u20131194. https:\/\/doi.org\/10.1016\/S0140-6736(21)00244-0","journal-title":"Lancet (London England)"},{"issue":"8","key":"414_CR46","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. (2021). Ponesimod: first approval. Drugs, 81(8), 957\u2013962. https:\/\/doi.org\/10.1007\/s40265-021-01523-z","journal-title":"Drugs"},{"issue":"9700","key":"414_CR47","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","volume":"374","author":"G Comi","year":"2009","unstructured":"Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H. P., Hillert, J., King, J., Komoly, S., Lubetzki, C., Montalban, X., Myhr, K. M., Ravnborg, M., Rieckmann, P., Wynn, D., Young, C., Filippi, M., & PreCISe study group. (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet (London England), 374(9700), 1503\u20131511. https:\/\/doi.org\/10.1016\/S0140-6736(09)61259-9","journal-title":"Lancet (London England)"},{"issue":"1","key":"414_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.22316","volume":"69","author":"G Comi","year":"2011","unstructured":"Comi, G., Cohen, J. A., Arnold, D. L., Wynn, D., Filippi, M., & FORTE Study Group. (2011). Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 69(1), 75\u201382. https:\/\/doi.org\/10.1002\/ana.22316","journal-title":"Annals of Neurology"},{"issue":"21","key":"414_CR49","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1038\/sj.onc.1203550","volume":"19","author":"HM Seidel","year":"2000","unstructured":"Seidel, H. M., Lamb, P., & Rosen, J. (2000). Pharmaceutical intervention in the JAK\/STAT signaling pathway. Oncogene, 19(21), 2645\u20132656. https:\/\/doi.org\/10.1038\/sj.onc.1203550","journal-title":"Oncogene"},{"key":"414_CR50","doi-asserted-by":"crossref","unstructured":"Nash, P., Kerschbaumer, A., D\u00f6rner, T., Dougados, M., Fleischmann, R. M., Geissler,K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., Takeuchi, T.,Trauner, M., Winthrop, K. L., de Wit, M., Aletaha, D., Baraliakos, X., Boehncke, W.H., Emery, P., Isaacs, J. D., Kremer, J.,\u2026 Smolen, J. S. (2021). Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors:a consensus statement. Annals of the rheumatic diseases, 80(1), 71\u201387. doi: 10.1136\/annrheumdis-2020-218398.","DOI":"10.1136\/annrheumdis-2020-218398"},{"issue":"6","key":"414_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A., Schett, G., & Mougiakakos, D. (2024). B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. The Lancet Neurology, 23(6), 615\u2013624. https:\/\/doi.org\/10.1016\/S1474-4422(24)00140-6","journal-title":"The Lancet Neurology"},{"issue":"6","key":"414_CR52","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L., Hagen, M., Rothe, T., Raimondo, M. G., Fagni, F., Tur, C., Wirsching, A., Wacker, J., Wilhelm, A., Auger, J. P., Pachowsky, M., Eckstein, M., Alivernini, S., Zoli, A., Kr\u00f6nke, G., Uderhardt, S., Bozec, A., D\u2019Agostino, M. A., Schett, G., & Grieshaber-Bouyer, R. (2024). Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nature Medicine, 30(6), 1593\u20131601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1","journal-title":"Nature Medicine"},{"issue":"5","key":"414_CR53","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester, G. R., Feist, E., Kellner, H., Braun, J., Iking-Konert, C., & Rubbert-Roth, A. (2011). Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Annals of the Rheumatic Diseases, 70(5), 755\u2013759. https:\/\/doi.org\/10.1136\/ard.2010.139725","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"414_CR54","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga, T. W., Fleischmann, R. M., Jasson, M., Radin, A. R., van Adelsberg, J., Fiore, S., Huang, X., Yancopoulos, G. D., Stahl, N., & Genovese, M. C. (2014). Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Annals of the Rheumatic Diseases, 73(9), 1626\u20131634. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204405","journal-title":"Annals of the Rheumatic Diseases"},{"key":"414_CR55","doi-asserted-by":"publisher","first-page":"101460","DOI":"10.1016\/j.msard.2019.101460","volume":"37","author":"H Hoshino","year":"2020","unstructured":"Hoshino, H., Shirai, Y., Konishi, H., Yamamura, T., & Shimizu, N. (2020). Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: a 12-year-old boy. Multiple Sclerosis and Related Disorders, 37, 101460. https:\/\/doi.org\/10.1016\/j.msard.2019.101460","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"414_CR56","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1186\/1756-0500-7-641","volume":"7","author":"H Sato","year":"2014","unstructured":"Sato, H., Kobayashi, D., Abe, A., Ito, S., Ishikawa, H., Nakazono, K., Murasawa, A., Kuroda, T., Nakano, M., & Narita, I. (2014). Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report. BMC Research Notes, 7, 641. https:\/\/doi.org\/10.1186\/1756-0500-7-641","journal-title":"BMC Research Notes"},{"issue":"2","key":"414_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1352458515623862","volume":"22","author":"P Beauchemin","year":"2016","unstructured":"Beauchemin, P., & Carruthers, R. (2016). MS arising during tocilizumab therapy for rheumatoid arthritis. Multiple Sclerosis (Houndmills Basingstoke England), 22(2), 254\u2013256. https:\/\/doi.org\/10.1177\/1352458515623862","journal-title":"Multiple Sclerosis (Houndmills Basingstoke England)"},{"issue":"S2","key":"414_CR58","first-page":"S129","volume":"52","author":"J Whitlock","year":"2015","unstructured":"Whitlock, J., Eidelman, B., & Whitlock, J. (2015). Demyelinating disease and axonal peripheral neuropathy in a 68-year-old male treated with tocilizumab for rheumatoid arthritis. Muscle & Nerve, 52(S2), S129.","journal-title":"Muscle &amp; Nerve"},{"issue":"12","key":"414_CR59","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., Dawson, K. T., & DEFINE Study Investigators. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine, 367(12), 1098\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa1114287","journal-title":"The New England Journal of Medicine"},{"key":"414_CR60","doi-asserted-by":"publisher","unstructured":"Singer, B. A., Arnold, D. L., Drulovic, J., Freedman, M. S., Gold, R., Gudesblatt,M., Jasinska, E., LaGanke, C. C., Naismith, R. T., Negroski, D., Oh, J., Hernandez Perez, M. A., Selmaj, K., Then Bergh, F., Wundes, A., Ziemssen, T., Castro-Borrero,W., Chen, H., Levin, S., Scaramozza, M.,\u2026 Wray, S. (2023). Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple sclerosis (Houndmills, Basingstoke, England), 29(14), 1795\u20131807. https:\/\/doi.org\/10.1177\/13524585231205708","DOI":"10.1177\/13524585231205708"},{"issue":"4","key":"414_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","volume":"85","author":"L Baird","year":"2011","unstructured":"Baird, L., & Dinkova-Kostova, A. T. (2011). The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology, 85(4), 241\u2013272. https:\/\/doi.org\/10.1007\/s00204-011-0674-5","journal-title":"Archives of Toxicology"},{"issue":"10","key":"414_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/ph13100306","volume":"13","author":"S Kourakis","year":"2020","unstructured":"Kourakis, S., Timpani, C. A., de Haan, J. B., Gueven, N., Fischer, D., & Rybalka, E. (2020). Dimethyl fumarate and its esters: a drug with broad clinical utility? Pharmaceuticals (Basel Switzerland), 13(10), 306. https:\/\/doi.org\/10.3390\/ph13100306","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"key":"414_CR63","unstructured":"Clinical trials database https:\/\/clinicaltrials.gov\/study\/NCT00810836?cond=NCT00810836&rank=1. Accessed 22 January 2025."},{"issue":"3","key":"414_CR64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jbspin.2018.07.006","volume":"86","author":"M Villedon de Naide","year":"2019","unstructured":"Villedon de Naide, M., Moisset, X., & Soubrier, M. (2019). Dimethyl fumarate induced migrating polyarthralgias. Joint Bone Spine, 86(3), 399\u2013400. https:\/\/doi.org\/10.1016\/j.jbspin.2018.07.006","journal-title":"Joint Bone Spine"},{"issue":"17","key":"414_CR65","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"CAMMS223 Trial Investigators, Coles, A. J., Compston, D. A., Selmaj, K. W., Lake, S. L., Moran, S., Margolin, D. H., Norris, K., & Tandon, P. K. (2008). Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. The New England Journal of Medicine, 359(17), 1786\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa0802670","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"414_CR66","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/art.1780381110","volume":"38","author":"ME Weinblatt","year":"1995","unstructured":"Weinblatt, M. E., Maddison, P. J., Bulpitt, K. J., Hazleman, B. L., Urowitz, M. B., Sturrock, R. D., Coblyn, J. S., Maier, A. L., Spreen, W. R., & Manna, V. K. (1995). CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis and Rheumatism, 38(11), 1589\u20131594. https:\/\/doi.org\/10.1002\/art.1780381110","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"414_CR67","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","volume":"35","author":"JD Isaacs","year":"1996","unstructured":"Isaacs, J. D., Manna, V. K., Rapson, N., Bulpitt, K. J., Hazleman, B. L., Matteson, E. L., Clair, S., Schnitzer, E. W., T. J., & Johnston, J. M. (1996). CAMPATH-1H in rheumatoid arthritis\u2013an intravenous dose-ranging study. British Journal of Rheumatology, 35(3), 231\u2013240. https:\/\/doi.org\/10.1093\/rheumatology\/35.3.231","journal-title":"British Journal of Rheumatology"},{"issue":"9","key":"414_CR68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman, C. H., O\u2019Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., & Sandrock, A. W.,AFFIRM Investigators (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine, 354(9), 899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397","journal-title":"The New England Journal of Medicine"},{"key":"414_CR69","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.msard.2020.101936","volume":"40","author":"E Su","year":"2020","unstructured":"Su, E., Novic, J., & Han, M. H. (2020). Emergence of rheumatoid arthritis following exposure to natalizumab. Multiple Sclerosis and Related Disorders, 40, 101936. https:\/\/doi.org\/10.1016\/j.msard.2020.101936","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"414_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland, M. L., Christensen, I. J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I. T., Kollerup, G., Linde, L., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S., Hostenkamp, G., \u00d8stergaard, M., & All Departments of Rheumatology in Denmark. (2010). Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism, 62(1), 22\u201332. https:\/\/doi.org\/10.1002\/art.27227","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"414_CR71","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","volume":"16","author":"V Pecoraro","year":"2017","unstructured":"Pecoraro, V., De Santis, E., Melegari, A., & Trenti, T. (2017). The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. a systematic review and meta-analysis. Autoimmunity Reviews, 16(6), 564\u2013575. https:\/\/doi.org\/10.1016\/j.autrev.2017.04.002","journal-title":"Autoimmunity Reviews"},{"key":"414_CR72","doi-asserted-by":"publisher","unstructured":"van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M., Woody, J. N., Hartung, H. P., & Polman, C. H. (1996). Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 47(6), 1531\u20131534. https:\/\/doi.org\/10.1212\/wnl.47.6.1531. PMID: 8960740.","DOI":"10.1212\/wnl.47.6.1531"},{"issue":"3","key":"414_CR73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"TNF neutralization in MS","year":"1999","unstructured":"TNF neutralization in MS. (1999). Results of a randomized, placebo-controlled multicenter study. the lenercept multiple sclerosis study group and the university of British Columbia MS\/MRI analysis group. Neurology, 53(3), 457\u2013465.","journal-title":"Neurology"},{"key":"414_CR74","doi-asserted-by":"publisher","first-page":"106145","DOI":"10.1016\/j.msard.2024.106145","volume":"92","author":"R Sacco","year":"2024","unstructured":"Sacco, R., Disanto, G., Pravat\u00e0, E., Mallucci, G., Maceski, A. M., Kuhle, J., Gobbi, C., & Zecca, C. (2024). De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: a pilot study. Multiple Sclerosis and Related Disorders, 92, 106145. https:\/\/doi.org\/10.1016\/j.msard.2024.106145","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"414_CR75","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/ITT.S288550","volume":"10","author":"LC Arneson","year":"2021","unstructured":"Arneson, L. C., Carroll, K. J., & Ruderman, E. M. (2021). Bruton\u2019s tyrosine kinase inhibition for the treatment of rheumatoid arthritis. ImmunoTargets and Therapy, 10, 333\u2013342. https:\/\/doi.org\/10.2147\/ITT.S288550","journal-title":"ImmunoTargets and Therapy"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00414-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:35:01Z","timestamp":1757252101000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00414-y","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Authors declare that there is no conflict of interest. Outside the submitted work, the Authors decelare the following.FFK received travel grants from Merck and Novartis and is a Hannover Medical School- and German Research Foundation (DFG)\u2013funded fellow as part of the Clinician Scientist Program (PRACTIS) at Hannover Medical School.TW received honoraria as speaker from Roche and Novartis.DE received honoraria for lecturing and research support from Novartis and Abbvie.DH has no conflicting interests to report.NM received travel grants and honoraria for lecturing from Biogen, Merck, and Novartis and is a Hannover Medical School- and German Research Foundation (DFG)\u2013funded fellow as part of the Clinician Scientist Program (PRACTIS) at Hannover Medical School.KFJ received research support from Else Kr\u00f6ner Fresenius Foundation and travel compensation and congress fee from Merck and Novartis.SN has received travel grants by Merck.LGL received a German Research Foundation (DFG)\u2013funded fellowship as part of the Clinician Scientist Program (Young Academy, Project number 413617135) at Hannover Medical School.KWS reports honoraria for lectures or travel reimbursements for attending meetings from Biogen, Merck, Bavarian Nordic and Bristol-Myers Squibb as well as research support from Bristol-Myers Squibb.LK reports grants from the German Research Foundation, the IZKF M\u00fcnster, Biogen, Novartis and Merck Serono. She serves on advisory boards and speakers\u2019 panels of Alexion, Argenx, Bayer, Biogen, Bristol-Myers Squibb, Grifols, Hexal, Horizon, Janssen, Merck Serono, Novartis, Roche, Sandoz, Sanofi, Santhera, Teva and Viatris.SP received honoraria for lecturing and compensation for serving on advisory boards from Sanofi, Merck, Biogen, Novartis, Roche, Hexal, and Alexion. He received travel reimbursement from Sanofi, Merck, Novartis, Roche, and Biogen. His research is financially supported by Merck, Novartis, and Biogen.RP received honoraria for lecturing and travel expenses from Biogen, Bristol-Myers Squibb, Horizon, Janssen Pharmaceuticals, Merck Serono, Novartis, Roche, and Sanofi-Aventis. His research is funded by Merck Serono and Novartis.MP received honoraria for lecturing and travel expenses for attending meetings from Alexion, ArgenX, Bayer Health Care, Biogen, Hexal, Merck Serono, Novartis, Roche, Sanofi-Aventis, Takeda and Teva. His research is funded by ArgenX, Biogen, Demecan, Hexal, Horizon, Merck Serono, Novartis, Roche, Viatris, Takeda and Teva. His research is funded by the the German Alzheimer Foundation and the Braun Foundation.CK received honoraria for lecturing and travel expenses for attending meetings from Alexion, Almirall, Astra Zenica, Bayer, Biogen, Biontech, Boehringer Ingelheim Bristol Myers-Squibb, C.T.I., Daiichi Sankyo, Docspert, Merck Serono, Mylan\/Viatris, Novartis, Pfizer, Roche, Sanofi-Aventis, Stada, Teva, Janssen-Cilag, Horizon Therapeutics, Medscape LLC, Baumgart Consultants, StreamedUp!, Hexal\/Sandoz, Agentur S\u00fcss.SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut f\u00fcr Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.TS reports research support from Alnylam Pharmaceuticals, CSL Behring, Merck, Novartis, Siemens; honoraria for lectures and travel expenses for attending meetings from Alexion, Alnylam Pharmaceuticals, argenx, Bayer Vital, Biogen, Bristol Myers Squibb, Celgene, Centogene, CSL Behring, Euroimmun, Grifols, Hexal AG, Horizon, Janssen-Cilag, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Swedish Orphan Biovitrum, Teva, Viatris; consultant fees from Alexion, Alnylam Pharmaceuticals, Biogen, Centogene, CSL Behring, Grifols, Hexal AG, Janssen-Cilag, Merck Serono, Novartis, Roche, Sanofi, Swedish Orphan Biovitrum, Viatris.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}